MCID: MYP006
MIFTS: 59

Myopia

Categories: Eye diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Myopia

MalaCards integrated aliases for Myopia:

Name: Myopia 12 77 26 38 30 56 6 45 15 41 74
Short-Sightedness 12 26
Near-Sightedness 12 26
Nearsightedness 26
Close Sighted 26
Short-Sighted 26
Near Vision 12
Nearsighted 26
Myopic 26

Classifications:



External Ids:

Disease Ontology 12 DOID:11830
KEGG 38 H02041
ICD9CM 36 367.1
MeSH 45 D009216
NCIt 51 C102533
SNOMED-CT 69 57190000
ICD10 34 H52.1
UMLS 74 C0027092

Summaries for Myopia

Genetics Home Reference : 26 Nearsightedness, also known as myopia, is an eye condition that causes blurry distance vision. People who are nearsighted have more trouble seeing things that are far away (such as when driving) than things that are close up (such as when reading or using a computer). If it is not treated with corrective lenses or surgery, nearsightedness can lead to squinting, eyestrain, headaches, and significant visual impairment.

MalaCards based summary : Myopia, also known as short-sightedness, is related to rare isolated myopia and marshall syndrome, and has symptoms including aniseikonia An important gene associated with Myopia is COL2A1 (Collagen Type II Alpha 1 Chain), and among its related pathways/superpathways is Degradation of the extracellular matrix. The drugs Atropine and Tropicamide have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and testes, and related phenotype is hearing/vestibular/ear.

Disease Ontology : 12 A refractive error characterized by the inability to see farther objects clearly.

Wikipedia : 77 Near-sightedness, also known as short-sightedness and myopia, is an eye disorder where light focuses in... more...

Related Diseases for Myopia

Diseases in the Myopia family:

Myopia 2, Autosomal Dominant Myopia 18, Autosomal Recessive
Myopia 3, Autosomal Dominant Myopia 17, Autosomal Dominant
Myopia 5, Autosomal Dominant Myopia 6
Myopia 7 Myopia 8
Myopia 9 Myopia 10
Myopia 11, Autosomal Dominant Myopia 12, Autosomal Dominant
Myopia 14 Myopia 16, Autosomal Dominant
Myopia 15, Autosomal Dominant Myopia 19, Autosomal Dominant
Myopia 20, Autosomal Dominant Myopia 21, Autosomal Dominant
Myopia 22, Autosomal Dominant Myopia 23, Autosomal Recessive
Myopia 24, Autosomal Dominant Myopia 25, Autosomal Dominant

Diseases related to Myopia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)
# Related Disease Score Top Affiliating Genes
1 rare isolated myopia 33.5 CHD7 COL2A1 FBN1 LRPAP1 P3H2 SCO2
2 marshall syndrome 33.1 COL11A1 COL2A1
3 refractive error 32.8 LRPAP1 PRIMPOL SCO2 SLC39A5 ZNF644
4 isolated ectopia lentis 32.5 ADAMTS17 FBN1
5 kniest dysplasia 31.8 COL11A1 COL2A1
6 strabismus 31.2 COL11A1 COL2A1 TYR
7 lens subluxation 30.5 FBN1 P3H2
8 vitreous syneresis 30.4 COL11A1 COL2A1
9 microcornea, myopic chorioretinal atrophy, and telecanthus 12.6
10 deafness and myopia 12.5
11 myopia 6 12.4
12 myopia 21, autosomal dominant 12.4
13 myopia 23, autosomal recessive 12.4
14 myopia, high, with cataract and vitreoretinal degeneration 12.4
15 degenerative myopia 12.4
16 myopia 22, autosomal dominant 12.4
17 myopia 24, autosomal dominant 12.4
18 myopia 26, x-linked, female-limited 12.4
19 myopia 12, autosomal dominant 12.4
20 myopia 13, x-linked 12.4
21 myopia 5, autosomal dominant 12.4
22 myopia 25, autosomal dominant 12.4
23 myopia 1, x-linked 12.3
24 myopia 10 12.3
25 epiphyseal dysplasia, multiple, with myopia and conductive deafness 12.3
26 polydactyly, postaxial, with progressive myopia 12.3
27 myopia 2, autosomal dominant 12.3
28 myopia 3, autosomal dominant 12.3
29 myopia 17, autosomal dominant 12.3
30 myopia 18, autosomal recessive 12.2
31 myopia 11, autosomal dominant 12.2
32 myopia 16, autosomal dominant 12.2
33 myopia 15, autosomal dominant 12.2
34 myopia 19, autosomal dominant 12.2
35 joint laxity, short stature, and myopia 12.2
36 myopia 7 12.2
37 myopia 8 12.2
38 myopia 9 12.2
39 myopia 14 12.2
40 myopia 20, autosomal dominant 12.2
41 blepharoptosis, myopia, and ectopia lentis 12.2
42 aplasia cutis congenita, high myopia, and cone-rod dysfunction 12.1
43 night blindness, congenital stationary, type 1a 12.1
44 sinus node disease and myopia 12.0
45 ophthalmoplegia, external, and myopia 12.0
46 spondyloepiphyseal dysplasia, myopia, and sensorineural deafness 12.0
47 dandy-walker malformation with mental retardation, macrocephaly, myopia, and brachytelephalangy 12.0
48 donnai-barrow syndrome 11.9
49 epiphyseal dysplasia of femoral head, myopia, and deafness 11.9
50 spinocerebellar degeneration with macular corneal dystrophy, congenital cataracts, and myopia 11.9

Graphical network of the top 20 diseases related to Myopia:



Diseases related to Myopia

Symptoms & Phenotypes for Myopia

UMLS symptoms related to Myopia:


aniseikonia

MGI Mouse Phenotypes related to Myopia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 9.02 CHD7 COL11A1 COL2A1 SLITRK6 TYR

Drugs & Therapeutics for Myopia

Drugs for Myopia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atropine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 5908-99-6, 51-55-8 174174
2
Tropicamide Approved, Investigational Phase 4,Phase 2,Not Applicable 1508-75-4 5593
3
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
4
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
5
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
6
Loteprednol Approved, Experimental Phase 4 82034-46-6, 129260-79-3 9865442 444025
7
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
8
Levofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 100986-85-4 149096
9
Ofloxacin Approved Phase 4,Phase 1,Phase 2,Not Applicable 82419-36-1 4583
10
Dipivefrin Approved Phase 4,Phase 2,Not Applicable 52365-63-6 3105
11
Povidone Approved Phase 4,Phase 2,Not Applicable 9003-39-8
12
Povidone-iodine Approved Phase 4,Phase 2 25655-41-8
13
Polihexanide Approved, Investigational Phase 4 28757-47-3
14
Hydrogen peroxide Approved, Vet_approved Phase 4,Not Applicable 7722-84-1 784
15
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
16
Ketorolac Approved Phase 4,Not Applicable 74103-06-3, 66635-83-4 3826
17
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
18
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
19
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
20
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 129497-78-5
21
Lactitol Investigational Phase 4,Not Applicable 585-88-6, 585-86-4 493591
22 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Bronchodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
30 Adjuvants, Anesthesia Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Mydriatics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Ophthalmic Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Gastrointestinal Agents Phase 4,Phase 2,Not Applicable
38 Anti-Infective Agents Phase 4,Phase 1,Phase 2,Not Applicable
39 Laxatives Phase 4
40 Cholinesterase Inhibitors Phase 4
41
Echothiophate Iodide Phase 4 6736-03-4 10547
42 Anti-Infective Agents, Local Phase 4,Phase 2,Not Applicable
43 Carboxymethylcellulose Sodium Phase 4
44 Micronutrients Phase 4,Phase 2,Not Applicable
45 Cathartics Phase 4
46 Trace Elements Phase 4,Phase 2,Not Applicable
47 cadexomer iodine Phase 4,Phase 2
48 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Nutrients Phase 4,Phase 2,Not Applicable
50 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 752)
# Name Status NCT ID Phase Drugs
1 Study of Myopia Prevention in Children With Low Concentration of Atropine Unknown status NCT00541177 Phase 4 atropine;tropicamide
2 Echothiophate Iodide for the Prevention of Progression of Myopia Unknown status NCT02544529 Phase 4 Echothiophate Iodide 0.03% Ophthalmic Solution;Carboxymethylcellulose Sodium (0.5%)
3 Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia. Unknown status NCT01917110 Phase 4
4 Comparison of Next Generation Laser Techniques of Myopia Correction: iDesign vs. SMILE Unknown status NCT03001401 Phase 4
5 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
6 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
7 Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study Unknown status NCT02974387 Phase 4 Fluorometholone(FML);Loteprednol (Lotemax)
8 A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK Unknown status NCT01977807 Phase 4
9 Multi Laser Platform Comparison Study for LASIK Unknown status NCT00770094 Phase 4
10 A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK Unknown status NCT02071576 Phase 4
11 A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia Unknown status NCT02112968 Phase 4
12 Effect of Orthokeratology Versus Spectacles on Myopia Progression in Chinese Children: A Crossover Trial Completed NCT02186184 Phase 4
13 Visual Outcomes and Contrast Sensitivity After Myopic LASIK Completed NCT01746589 Phase 4
14 Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds Completed NCT00564213 Phase 4 PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds
15 A Comparison of PRK and LASIK for Correction of Myopia Completed NCT00404105 Phase 4
16 An Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients Completed NCT01173198 Phase 4
17 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
18 SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Completed NCT03409250 Phase 4 Ranibizumab, Lucentis
19 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Completed NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
20 Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes Completed NCT01387360 Phase 4
21 Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction Completed NCT01225952 Phase 4
22 Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap Completed NCT01693939 Phase 4
23 The Effects of Low Dose Atropine on Choroidal Thickness Completed NCT03544827 Phase 4 Atropine;Atropine
24 The Influence of Atropine on Choroidal Thickness Completed NCT03158142 Phase 4 Atropine Sulfate 1% Oph Soln
25 Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK Completed NCT00821236 Phase 4
26 Clinical Study of Approved Contact Lenses Completed NCT03351101 Phase 4
27 BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study Completed NCT02537730 Phase 4
28 Clinical Evaluation of Daily Disposable Contact Lenses Completed NCT02097030 Phase 4
29 Daily Disposable Comparison Study Completed NCT02094677 Phase 4
30 Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist Completed NCT02024698 Phase 4
31 Evaluation of Stenfilcon A Versus Etafilcon A Completed NCT01809834 Phase 4
32 Clinical Performance of Stenfilcon A Versus Filcon II 3 Completed NCT01808209 Phase 4
33 Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses Completed NCT01707238 Phase 4
34 Evaluation of Comfilcon A and Senofilcon A Lenses Completed NCT01695369 Phase 4
35 Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK Completed NCT00889941 Phase 4
36 Comparative Performance of PureVision, Acuvue Oasys and O2Optix Completed NCT00640341 Phase 4
37 Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision Completed NCT00627302 Phase 4 PEG-400;Systane
38 Long-term Effects of Laser Refractive Surgery Completed NCT00350246 Phase 4
39 Effects of Contact Lens Care Regimens on the Corneal Epithelium Completed NCT00349882 Phase 4 Marketed multipurpose disinfection regimen
40 Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort Completed NCT00349843 Phase 4 Marketed soft lens multipurpose disinfection regimen
41 Daily Wear Corneal Infiltrative Event Study Completed NCT00937105 Phase 4
42 Visual Performance After RESTOR Implantation Completed NCT01065064 Phase 4
43 The Impact of Soft Contact Lens Attributes on Symptoms Associated With Digital Eye Strain in Symptomatic Soft Contact Lens Wearers Completed NCT03585790 Phase 4
44 Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface Completed NCT01250925 Phase 4 ReNu MultiPlus® MultiPurpose Solution;OPTI-FREE® RepleniSH®;Clear Care®
45 Corneal and Conjunctival Sensitivity and Staining Study Completed NCT00455455 Phase 4 Optifree RepleniSH Multipurpose Disinfecting Solution;ReNu Multiplus Multipurpose Solution
46 Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK Completed NCT00347204 Phase 4 ketorolac (Acular LS);Nepafenac (Nevanac)
47 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
48 Evaluation of 3 Intraocular Lenses Following Lens Extraction Completed NCT01122576 Phase 4
49 Efficacy and Safety of Adding Atracurium to Percaruncular Block for High Myopes Undergoing Cataract Surgery Completed NCT03243500 Phase 4 Atracurium;Lidocaine 2%;Bupivacaine 0.5%;hyaluronidase powder
50 Clinical Evaluation of the One-Piece Tecnis Multifocal Intraocular Lens (IOL) Completed NCT01210807 Phase 4

Search NIH Clinical Center for Myopia

Cochrane evidence based reviews: myopia

Genetic Tests for Myopia

Genetic tests related to Myopia:

# Genetic test Affiliating Genes
1 Myopia 30

Anatomical Context for Myopia

MalaCards organs/tissues related to Myopia:

42
Eye, Retina, Testes, Endothelial, Brain, Bone, Skin

Publications for Myopia

Articles related to Myopia:

(show top 50) (show all 3421)
# Title Authors Year
1
Corrigendum to "Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression" [EBioMedicine 28 (2018) 274-286]. ( 30885727 )
2019
2
Interocular Symmetry of Fixation, Optic Disc, and Corneal Astigmatism in Bilateral High Myopia: The Shanghai High Myopia Study. ( 30783557 )
2019
3
Posterior Chamber Phakic Intraocular Lens Implantation for the Correction of Myopia and Myopic Astigmatism: A Retrospective 10-Year Follow-Up Study. ( 31078536 )
2019
4
Three-year outcomes of small incision lenticule extraction (SMILE) and femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK) for myopia and myopic astigmatism. ( 30061116 )
2019
5
Myopia and myopic astigmatism photorefractive keratectomy: applying an advanced multiple regression-derived nomogram. ( 30121713 )
2019
6
Dome-shaped macula: a potential protective factor for visual acuity after cataract surgery in patients with high myopia. ( 30602448 )
2019
7
Near vision in individuals with Down syndrome: a vision screening study. ( 30914784 )
2019
8
Magnetic resonance imaging findings of age-related distance esotropia in Japanese patients with high myopia. ( 30671656 )
2019
9
Strain-Dependent Differences in Sensitivity to Myopia-Inducing Stimuli in Guinea Pigs and Role of Choroid. ( 30913566 )
2019
10
Imaging of Pathologic Myopia. ( 30924327 )
2019
11
Refractive Change and Incidence of Myopia Among A Group of Highly Selected Senior High School Students in China: A Prospective Study in An Aviation Cadet Prerecruitment Class. ( 30933262 )
2019
12
Prevalence and Phenotypes of Age-Related Macular Degeneration in Eyes With High Myopia. ( 30938774 )
2019
13
Interaction between lifestyle and genetic susceptibility in myopia: the Generation R study. ( 30945054 )
2019
14
Choroidal Thickness and Associated Factors among Adult Myopia: A Baseline Report from a Medical University Student Cohort. ( 30957606 )
2019
15
Visual and optical quality outcomes of SMILE and FS-LASIK for myopia in the very early phase after surgery. ( 30961593 )
2019
16
Prevalence and Associations of Posterior Segment Manifestations in a Cohort of Egyptian Patients with Pathological Myopia. ( 30964360 )
2019
17
Effect of High Myopia on Optic Nerve Head by Confocal Scanning Laser Ophthalmoscopy in Nepalese Eyes. ( 30977328 )
2019
18
Incidence and management of symptomatic dry eye related to LASIK for myopia, with topical cyclosporine A. ( 30988596 )
2019
19
Accommodation and its role in myopia progression and control with soft contact lenses. ( 30994197 )
2019
20
The Relation of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio with High Axial Myopia. ( 30994377 )
2019
21
Population prevalence of myopia, glasses wear and free glasses acceptance among minority versus Han schoolchildren in China. ( 30998750 )
2019
22
Visual Acuity in Pathological Myopia Is Correlated With the Photoreceptor Myoid and Ellipsoid Zone Thickness and Affected by Choroid Thickness. ( 31013344 )
2019
23
Long-Term Natural Course of Pathologic Myopia in Chinese Patients. ( 31016036 )
2019
24
Relationship Between the Shift of the Retinal Artery Associated With Myopia and Ocular Response Analyzer Waveform Parameters. ( 31016069 )
2019
25
Fixation Characteristics in Highly Myopic Eyes: the Shanghai High Myopia Study. ( 31019218 )
2019
26
Association between retinal microvasculature and optic disc alterations in high myopia. ( 31019262 )
2019
27
Cytokine fibroblast growth factor 10 (FGF10) polymorphisms are associated with risk of myopia in young children. ( 31021460 )
2019
28
Clinical outcomes of mechanical and transepithelial photorefractive keratectomy in low myopia with a large ablation zone. ( 31029476 )
2019
29
Bilateral capsulorhexis phimosis with full closure and intraocular lens crimping in one eye in a patient with high myopia: May consultation #1. ( 31030783 )
2019
30
Phenotypic high myopia in X-linked retinitis pigmentosa secondary to a novel mutation in the RPGR gene. ( 31033374 )
2019
31
Recent updates on myopia control: preventing progression 1 diopter at a time. ( 31033732 )
2019
32
Two-year observation of posterior corneal elevations after small incision lenticule extraction (SMILE) for myopia higher than -10 dioptres. ( 31036587 )
2019
33
Artiflex foldable lens for myopia correction results of 10 years of follow-up. ( 31036878 )
2019
34
Glaucoma in myopia: diagnostic dilemmas. ( 31040131 )
2019
35
Bifocal & Atropine in Myopia Study: Baseline Data and Methods. ( 31046016 )
2019
36
Clinical Evaluation of LASEK for High Myopia Correction between the Triple-A Profile and the Zyoptix Tissue Saving Profile. ( 31061728 )
2019
37
Quantile regression analysis reveals widespread evidence for gene-environment or gene-gene interactions in myopia development. ( 31069276 )
2019
38
Choroidal changes in human myopia: insights from optical coherence tomography imaging. ( 30565333 )
2019
39
The Lowdown on Low-Concentration Atropine for Myopia Progression. ( 30577908 )
2019
40
Disordered sleep and myopia among adolescents: a propensity score matching analysis. ( 30601071 )
2019
41
Aripiprazole induced myopia - case report and literature review: Aripiprazole induced myopia. ( 30605046 )
2019
42
Lack of cone mediated retinal function increases susceptibility to form-deprivation myopia in mice. ( 30605665 )
2019
43
Establishment of an induced pluripotent stem cell line (FDEENTi001-A) from a patient with pathological myopia. ( 30611020 )
2019
44
Effects of time-of-day on inhibition of lens-induced myopia by quinpirole, pirenzepine and atropine in chicks. ( 30629959 )
2019
45
Combined Atropine with Orthokeratology (AOK) for Myopia Control: Study Design and Preliminary Results. ( 30632410 )
2019
46
Five-year results of small incision lenticule extraction (SMILE) and femtosecond laser LASIK (FS-LASIK) for myopia. ( 30632671 )
2019
47
15-Month Visual Outcomes and Corneal Power Changes of SMILE in Treating High Myopia With Maximum Myopic Meridian Exceeding 10.00 D. ( 30633785 )
2019
48
Evaluation of Different IOL Calculation Formulas of the ASCRS Calculator in Eyes After Corneal Refractive Laser Surgery for Myopia With Multifocal IOL Implantation. ( 30633788 )
2019
49
Imaging in myopia: potential biomarkers, current challenges and future developments. ( 30636210 )
2019
50
Longitudinal Changes in Spherical Equivalent Refractive Error Among Children With Preschool Myopia. ( 30640967 )
2019

Variations for Myopia

ClinVar genetic disease variations for Myopia:

6 (show top 50) (show all 52)
# Gene Variation Type Significance SNP ID Assembly Location
1 TYR NM_000372.4(TYR): c.1A> G (p.Met1Val) single nucleotide variant Pathogenic rs28940881 GRCh37 Chromosome 11, 88911122: 88911122
2 TYR NM_000372.4(TYR): c.1A> G (p.Met1Val) single nucleotide variant Pathogenic rs28940881 GRCh38 Chromosome 11, 89177954: 89177954
3 COL2A1 NM_033150.2(COL2A1): c.2503C> T (p.Arg835Cys) single nucleotide variant Pathogenic rs121912882 GRCh37 Chromosome 12, 48373317: 48373317
4 COL2A1 NM_033150.2(COL2A1): c.2503C> T (p.Arg835Cys) single nucleotide variant Pathogenic rs121912882 GRCh38 Chromosome 12, 47979534: 47979534
5 SLC25A4 NM_001151.3(SLC25A4): c.368C> A (p.Ala123Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912683 GRCh37 Chromosome 4, 186066174: 186066174
6 SLC25A4 NM_001151.3(SLC25A4): c.368C> A (p.Ala123Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912683 GRCh38 Chromosome 4, 185145020: 185145020
7 TYR NM_000372.4(TYR): c.1037-7T> A single nucleotide variant Pathogenic/Likely pathogenic rs61754381 GRCh37 Chromosome 11, 88960984: 88960984
8 TYR NM_000372.4(TYR): c.1037-7T> A single nucleotide variant Pathogenic/Likely pathogenic rs61754381 GRCh38 Chromosome 11, 89227816: 89227816
9 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh37 Chromosome 11, 47433573: 47433573
10 SLC39A13 NM_152264.4(SLC39A13): c.398C> T (p.Thr133Met) single nucleotide variant Conflicting interpretations of pathogenicity rs140574574 GRCh38 Chromosome 11, 47412022: 47412022
11 COL4A4 NM_000092.4(COL4A4): c.2320G> C (p.Gly774Arg) single nucleotide variant Likely pathogenic rs569681869 GRCh37 Chromosome 2, 227924184: 227924184
12 COL4A4 NM_000092.4(COL4A4): c.2320G> C (p.Gly774Arg) single nucleotide variant Likely pathogenic rs569681869 GRCh38 Chromosome 2, 227059468: 227059468
13 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh37 Chromosome 12, 123001951: 123001951
14 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh38 Chromosome 12, 122517404: 122517404
15 46;X;t(X;9)(p22.2;p13)dn Translocation Uncertain significance
16 46;XY;t(2;14)(p23;q13)dn Translocation Uncertain significance
17 46;XY;t(5;15)(q11.2;q24) Translocation Pathogenic
18 ZNF469 NM_001127464.2(ZNF469): c.470G> A (p.Gly157Glu) single nucleotide variant Uncertain significance rs781096189 GRCh38 Chromosome 16, 88427940: 88427940
19 ZNF469 NM_001127464.2(ZNF469): c.470G> A (p.Gly157Glu) single nucleotide variant Uncertain significance rs781096189 GRCh37 Chromosome 16, 88494348: 88494348
20 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh37 Chromosome MT, 3275: 3275
21 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh38 Chromosome MT, 3275: 3275
22 POGZ NM_015100.3(POGZ): c.402_409dupTGCCAATC (p.His137Leufs) duplication Likely pathogenic rs1057518799 GRCh38 Chromosome 1, 151430716: 151430723
23 POGZ NM_015100.3(POGZ): c.402_409dupTGCCAATC (p.His137Leufs) duplication Likely pathogenic rs1057518799 GRCh37 Chromosome 1, 151403192: 151403199
24 CHD7 NM_017780.3(CHD7): c.6892C> T (p.Gln2298Ter) single nucleotide variant Pathogenic rs1057518891 GRCh37 Chromosome 8, 61767038: 61767038
25 CHD7 NM_017780.3(CHD7): c.6892C> T (p.Gln2298Ter) single nucleotide variant Pathogenic rs1057518891 GRCh38 Chromosome 8, 60854479: 60854479
26 FBN1 NM_000138.4(FBN1): c.6800A> T (p.Asn2267Ile) single nucleotide variant Pathogenic rs1057518812 GRCh38 Chromosome 15, 48430742: 48430742
27 FBN1 NM_000138.4(FBN1): c.6800A> T (p.Asn2267Ile) single nucleotide variant Pathogenic rs1057518812 GRCh37 Chromosome 15, 48722939: 48722939
28 FBN1 NM_000138.4(FBN1): c.1481G> T (p.Cys494Phe) single nucleotide variant Likely pathogenic rs1057518881 GRCh37 Chromosome 15, 48805853: 48805853
29 FBN1 NM_000138.4(FBN1): c.1481G> T (p.Cys494Phe) single nucleotide variant Likely pathogenic rs1057518881 GRCh38 Chromosome 15, 48513656: 48513656
30 FBN1 NM_000138.4(FBN1): c.840_843delTGAA (p.Asn280Lysfs) deletion Pathogenic rs1057518909 GRCh37 Chromosome 15, 48826296: 48826299
31 FBN1 NM_000138.4(FBN1): c.840_843delTGAA (p.Asn280Lysfs) deletion Pathogenic rs1057518909 GRCh38 Chromosome 15, 48534099: 48534102
32 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh38 Chromosome 16, 15724166: 15724166
33 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh37 Chromosome 16, 15818023: 15818023
34 EP300 NM_001429.3(EP300): c.2053+4A> T single nucleotide variant Uncertain significance rs1057518889 GRCh37 Chromosome 22, 41537230: 41537230
35 EP300 NM_001429.3(EP300): c.2053+4A> T single nucleotide variant Uncertain significance rs1057518889 GRCh38 Chromosome 22, 41141226: 41141226
36 AFF2 NM_002025.3(AFF2): c.3209A> G (p.His1070Arg) single nucleotide variant Uncertain significance rs1057518785 GRCh37 Chromosome X, 148049164: 148049164
37 AFF2 NM_002025.3(AFF2): c.3209A> G (p.His1070Arg) single nucleotide variant Uncertain significance rs1057518785 GRCh38 Chromosome X, 148967634: 148967634
38 CACNA1F NM_005183.3(CACNA1F): c.694A> T (p.Lys232Ter) single nucleotide variant Likely pathogenic rs1057518829 GRCh37 Chromosome X, 49086805: 49086805
39 CACNA1F NM_005183.3(CACNA1F): c.694A> T (p.Lys232Ter) single nucleotide variant Likely pathogenic rs1057518829 GRCh38 Chromosome X, 49230343: 49230343
40 COL11A1 NM_080629.2(COL11A1): c.4084_4101delTCTGGTGAGGCTGGCCCA (p.Ser1362_Pro1367del) deletion Likely pathogenic rs1553200431 GRCh37 Chromosome 1, 103377736: 103377753
41 COL11A1 NM_080629.2(COL11A1): c.4084_4101delTCTGGTGAGGCTGGCCCA (p.Ser1362_Pro1367del) deletion Likely pathogenic rs1553200431 GRCh38 Chromosome 1, 102912180: 102912197
42 COL4A4 NM_000092.4(COL4A4): c.4394G> A (p.Gly1465Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs533297350 GRCh38 Chromosome 2, 227010441: 227010441
43 COL4A4 NM_000092.4(COL4A4): c.4394G> A (p.Gly1465Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs533297350 GRCh37 Chromosome 2, 227875157: 227875157
44 TNC NM_002160.3(TNC): c.890A> G (p.Asn297Ser) single nucleotide variant Uncertain significance rs1554717312 GRCh37 Chromosome 9, 117849120: 117849120
45 TNC NM_002160.3(TNC): c.890A> G (p.Asn297Ser) single nucleotide variant Uncertain significance rs1554717312 GRCh38 Chromosome 9, 115086841: 115086841
46 ZNF469 NM_001127464.2(ZNF469): c.2569A> G (p.Asn857Asp) single nucleotide variant Uncertain significance rs1555518955 GRCh37 Chromosome 16, 88496447: 88496447
47 ZNF469 NM_001127464.2(ZNF469): c.2569A> G (p.Asn857Asp) single nucleotide variant Uncertain significance rs1555518955 GRCh38 Chromosome 16, 88430039: 88430039
48 ZNF469 NM_001127464.2(ZNF469): c.9448G> A (p.Gly3150Ser) single nucleotide variant Uncertain significance rs887755283 GRCh38 Chromosome 16, 88437002: 88437002
49 ZNF469 NM_001127464.2(ZNF469): c.9448G> A (p.Gly3150Ser) single nucleotide variant Uncertain significance rs887755283 GRCh37 Chromosome 16, 88503410: 88503410
50 subset of 22 genes:FLCN; RAI1 GRCh37/hg19 17p11.2(chr17: 16936603-18184130) copy number loss Pathogenic GRCh37 Chromosome 17, 16936603: 18184130

Expression for Myopia

Search GEO for disease gene expression data for Myopia.

Pathways for Myopia

Pathways related to Myopia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.58 COL11A1 COL2A1 FBN1 P3H2

GO Terms for Myopia

Cellular components related to Myopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.46 COL11A1 COL2A1 FBN1 NYX
2 endoplasmic reticulum lumen GO:0005788 9.26 COL11A1 COL2A1 FBN1 P3H2
3 basement membrane GO:0005604 8.8 COL2A1 FBN1 P3H2

Biological processes related to Myopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 skeletal system development GO:0001501 9.63 CHD7 COL2A1 FBN1
2 camera-type eye development GO:0043010 9.54 CHD7 FBN1 SLITRK6
3 eye development GO:0001654 9.48 SCO2 SLC39A5
4 sensory perception of sound GO:0007605 9.46 CHD7 COL11A1 COL2A1 SLITRK6
5 innervation GO:0060384 9.43 CHD7 SLITRK6
6 heart morphogenesis GO:0003007 9.43 CHD7 COL11A1 COL2A1
7 cartilage condensation GO:0001502 9.4 COL11A1 COL2A1
8 visual perception GO:0007601 9.35 COL11A1 COL2A1 NYX SLITRK6 TYR
9 proteoglycan metabolic process GO:0006029 9.32 COL11A1 COL2A1
10 inner ear morphogenesis GO:0042472 8.92 CHD7 COL11A1 COL2A1 SLITRK6

Molecular functions related to Myopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.13 COL11A1 FBN1 LRPAP1
2 extracellular matrix structural constituent GO:0005201 8.8 COL11A1 COL2A1 FBN1

Sources for Myopia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....